Clinical Trials
91
14 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1956
Active, not recruiting
1
1.1%
Completed
43
47.3%
Not yet recruiting
13
14.3%
Recruiting
17
18.7%
Suspended
1
1.1%
Terminated
1
1.1%
Unknown
15
16.5%
No approval data available
- HKBU's Institute of Creativity and School of Chinese Medicine hosted the inaugural "CxC" Series session on 11 August, themed around autophagy and its potential against neurodegenerative diseases. - Professor Noboru Mizushima of The University of Tokyo outlined autophagy's molecular mechanisms and reversible ATG knockdown mouse models showing restored motor and memory functions. - Professor Li Min presented HKBU's discovery of autophagy-regulating neuroprotective agents derived from Uncaria rhynchophylla (Gouteng) and curcumin derivatives. - The event highlighted how traditional Chinese medicine wisdom is integrating with molecular science to address the rising global prevalence of Alzheimer's and Parkinson's diseases.
- Researchers at RMIT University have developed nanodots made from molybdenum oxide that selectively kill cancer cells while largely sparing healthy tissue. - Laboratory tests demonstrated the nanodots destroyed three times more cervical cancer cells than healthy cells within 24 hours without requiring light activation. - The particles work by releasing reactive oxygen molecules that trigger programmed cell death in cancer cells, which are already under higher stress than healthy cells. - The research represents an international collaboration between RMIT University, The Florey Institute, and several Chinese institutions, though testing remains limited to laboratory-grown cells.
- An aptamer developed by Hong Kong Baptist University (HKBU) for treating X-linked hypophosphatemia (XLH) has received Orphan Drug Designation from the FDA. - The FDA also granted the aptamer a Rare Pediatric Disease Designation, potentially accelerating its clinical translation and benefiting XLH patients. - Preclinical studies suggest the aptamer, Apc001, can promote bone formation and increase blood phosphorus levels without increasing cardiovascular risk. - Clinical trials for Apc001 are scheduled to begin in both Mainland China and the U.S., following completion of pilot scale production and preclinical toxicological assessment.
